NOTIFICATION

The following notification is being circulated in accordance with Article 10.6

|  |  |
| --- | --- |
| **1.** | **Notifying Member:** PHILIPPINES**If applicable, name of local government involved (Article 3.2 and 7.2):**  |
| **2.** | **Agency responsible:** DR. OSCAR G. GUTIERREZ, JR., MPAOfficer-in-Charge Director GeneralFood and Drug AdministrationDEPARTMENT OF HEALTH**Name and address (including telephone and fax numbers, email and website addresses, if available) of agency or authority designated to handle comments regarding the notification shall be indicated if different from above:** Jesusa Joyce N. Cirunay, RPhDirector IVCenter for Drug Regulation and ResearchFood and Drug AdministrationDEPARTMENT OF HEALTHEmail: cdrr.od@fda.gov.ph; cdrr.sds@fda.gov.ph[www.fda.gov.ph](http://www.fda.gov.ph)  |
| **3.** | **Notified under Article 2.9.2 [****X],** **2.10.1 [****],** **5.6.2 [****],** **5.7.1 [****], 3.2 [****], 7.2 [****],** **other****:**  |
| **4.** | **Products covered (HS or CCCN where applicable, otherwise national tariff heading. ICS numbers may be provided in addition, where applicable):** WHO-prequalified pharmaceutical products and vaccines |
| **5.** | **Title, number of pages and language(s) of the notified document:** Implementing Guidelines on the Collaborative Procedure for the Accelerated Registration of World Health Organization (WHO) – Prequalified Pharmaceutical Products and Vaccines; (6 page(s), in English) |
| **6.** | **Description of content:** The proposed issuance aims to provide the implementing guidelines of the collaborative procedure for accelerated registration of WHO-prequalified pharmaceutical products and vaccines to guide the concerned stakeholders. |
| **7.** | **Objective and rationale, including the nature of urgent problems where applicable:** The FDA, together with the DOH, are tasked to ensure that there is a constant supply of drugs, including vaccines, and that there is facilitated access to safe, effective, and quality drugs. Given the current resource constraints affecting drug regulation, collaboration and regulatory convergence with international organizations such as the WHO are necessary. This Circular aims to provide the implementing guidelines of AO No. 2020-0044 which adopted the collaborative procedure for accelerated registration of WHO-prequalified pharmaceutical products and vaccines.; Protection of human health or safety |
| **8.** | **Relevant documents:** * Republic Act No. 9711 "Food and Drug Administration (FDA) Act of 2009"
* Administrative Order No. 2020-0044 "Adoption of the Collaborative Procedure for the Accelerated Registration of World Health Organization (WHO) – Prequalified Pharmaceutical Products and Vaccines"
* World Health Organization (WHO) Technical Report Series, No. 996, 2016 (Annex 8, Collaborative procedure between the World Health Organization (WHO) Prequalification Team and national regulatory authorities in the assessment and accelerated national registration of WHO-prequalified pharmaceutical products and vaccines)
 |
| **9.** | **Proposed date of adoption:** This Circular shall take effect fifteen (15) calendar days after publication in one (1) newspaper of general circulation and upon filing with the University of the Philippines, Office of the National Administrative Register (ONAR)**Proposed date of entry into force:** Upon effectivity |
| **10.** | **Final date for comments:** 17 June 2022 |
| **11.** | **Texts available from: National enquiry point [****X]** **or address, telephone and fax numbers and email and website addresses, if available, of other body:** Mr. Neil P. CatajayDirectorBureau of Philippine StandardsDepartment of Trade and Industry3F Trade and Industry Building361 Sen. Gil Puyat AvenueMakati CityPhilippinesTel: (632) 7791.3127 ; (632) 7791.3128Email: bps@dti.gov.phWebsite: <http://www.bps.dti.gov.ph><https://www.fda.gov.ph/draft-for-comments-implementing-guidelines-on-the-collaborative-procedure-for-the-accelerated-registration-of-world-health-organization-who-prequalified-pharmaceutical-products-and-vacc/><https://members.wto.org/crnattachments/2022/TBT/PHL/22_4120_00_e.pdf><https://members.wto.org/crnattachments/2022/TBT/PHL/22_4120_01_e.pdf><https://members.wto.org/crnattachments/2022/TBT/PHL/22_4120_02_e.pdf><https://members.wto.org/crnattachments/2022/TBT/PHL/22_4120_03_e.pdf><https://members.wto.org/crnattachments/2022/TBT/PHL/22_4120_04_e.pdf><https://members.wto.org/crnattachments/2022/TBT/PHL/22_4120_05_e.pdf><https://members.wto.org/crnattachments/2022/TBT/PHL/22_4120_06_e.pdf><https://members.wto.org/crnattachments/2022/TBT/PHL/22_4120_07_e.pdf> |